[Metabolic or immunometabolic syndrome?].
Understanding the risk and pathogenesis of the numerous disorders including the insulin resistance/metabolic syndrome has changed meaningfully in the recent years. The remarkable similarity of the risk factors of cardiovascular disease, type 2 diabetes mellitus, obesity and atherogenic dyslipidemia induced to search for their pathophysiology. The aim of these examinations was to determine if the inflammatory state is a soil of the metabolic syndrome as in atherosclerosis? Increasing number of studies demonstrates a series of statistically significant correlations between the inflammatory markers and diseases present in the metabolic syndrome. It allows for the reasonable basis of hypothesis that chronic, mild inflammatory state underlies not only the cardiovascular disease, but also is the soil of the metabolic syndrome pathologies and its complications development. Both associations between the inflammatory mediators as CRP, fibrinogen, alpha1-glycoproteins, leptin, TNFalpha, PAI-1 and the metabolic syndrome variables, chiefly obesity, seem to suggest that both atherosclerosis and insulin resistance are the results of chronic activation of the nonspecific (innate) immune system. According to this hypothesis, daily stresses as traumas, infections and emotions would lead to primary immune and neuroendocrine systems alterations. By this manner, whole body metabolic disorders and metabolic syndrome component progressive reveal would approach. In this context, metabolic syndrome might be defined as an immunemetabolic disease.
Kliniki Chorób Wewnetrznych i Farmakologii Klinicznej.
Janusz
J
Wysocki
Szymon
S
Skoczyński
Agnieszka
A
Strózik
Beata
B
Hochuł
Magdalena
M
Zyguła
D001161:Arteriosclerosis / Q000276:immunology; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate; D018836:Inflammation Mediators / Q000276:immunology / Q000378:metabolism*; D007333:Insulin Resistance; D024821:Metabolic Syndrome / Q000276:immunology*; D009765:Obesity / Q000276:immunology; D012307:Risk Factors
D016207:Cytokines; D018836:Inflammation Mediators